Abstract
Background/Objective: Statins have well-established cardiovascular benefits, and recent evidence suggests that discontinuing statin therapy after acute myocardial infarction (AMI) is harmful. Our objective was to assess the association between statin discontinuation post-AMI and 1-year all-cause mortality in a real world setting.
Methods: Data on survivors of AMI between 2000 and 2007 were extracted from the hospital discharge summary database of Quebec and the provincial physician and drug claims database. Statin prescription filling was used to establish cohort groups. Previous statin use was defined as having filled a statin prescription in the 90 days pre-AMI, while post-AMI statin use was filling a prescription between discharge from hospital post-AMI and 90 days post-discharge. AMI patients who survived 90 days (n=48,229) were divided into 4 groups: i) non-users (n=11,657), did not receive statins pre- or post- AMI (reference group), ii) starters (n=22,452), received statins only post-AMI, iii) stoppers (n=488), received statins prebut not post-AMI, and, iv) users (n=13,632), received statins pre- and post-AMI. Cox proportional hazards models were used to calculate hazard ratios (HR).
Results: Compared with non-users, stoppers had increased 1-year all-cause mortality (adjusted HR 1.36; 95% CI 1.08- 1.70, P=0.008). Starters (HR 0.65; 95% CI 0.59-0.71, P<0.0001) and users (HR 0.81; 95% CI 0.74-0.88, P<0.0001) had lower mortality than non-users.
Conclusion: Discontinuation of statins in survivors of AMI was associated with an increase in 1-year all-cause mortality. Physicians should use caution when discontinuing statins post-AMI.
Keywords: Statin discontinuation, acute myocardial infarction, all-cause mortality, statin adherence.
Current Vascular Pharmacology
Title:Different Patterns of Statin Use in Patients with Acute Myocardial Infarction
Volume: 12 Issue: 6
Author(s): Stella S. Daskalopoulou, Robert J. Doonan, Joseph A. Delaney and Louise Pilote
Affiliation:
Keywords: Statin discontinuation, acute myocardial infarction, all-cause mortality, statin adherence.
Abstract: Background/Objective: Statins have well-established cardiovascular benefits, and recent evidence suggests that discontinuing statin therapy after acute myocardial infarction (AMI) is harmful. Our objective was to assess the association between statin discontinuation post-AMI and 1-year all-cause mortality in a real world setting.
Methods: Data on survivors of AMI between 2000 and 2007 were extracted from the hospital discharge summary database of Quebec and the provincial physician and drug claims database. Statin prescription filling was used to establish cohort groups. Previous statin use was defined as having filled a statin prescription in the 90 days pre-AMI, while post-AMI statin use was filling a prescription between discharge from hospital post-AMI and 90 days post-discharge. AMI patients who survived 90 days (n=48,229) were divided into 4 groups: i) non-users (n=11,657), did not receive statins pre- or post- AMI (reference group), ii) starters (n=22,452), received statins only post-AMI, iii) stoppers (n=488), received statins prebut not post-AMI, and, iv) users (n=13,632), received statins pre- and post-AMI. Cox proportional hazards models were used to calculate hazard ratios (HR).
Results: Compared with non-users, stoppers had increased 1-year all-cause mortality (adjusted HR 1.36; 95% CI 1.08- 1.70, P=0.008). Starters (HR 0.65; 95% CI 0.59-0.71, P<0.0001) and users (HR 0.81; 95% CI 0.74-0.88, P<0.0001) had lower mortality than non-users.
Conclusion: Discontinuation of statins in survivors of AMI was associated with an increase in 1-year all-cause mortality. Physicians should use caution when discontinuing statins post-AMI.
Export Options
About this article
Cite this article as:
Daskalopoulou S. Stella, Doonan J. Robert, Delaney A. Joseph and Pilote Louise, Different Patterns of Statin Use in Patients with Acute Myocardial Infarction, Current Vascular Pharmacology 2014; 12 (6) . https://dx.doi.org/10.2174/157016111206141210121017
DOI https://dx.doi.org/10.2174/157016111206141210121017 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Cardiovascular Drugs Inducing QT Prolongation: Facts and Evidence
Current Drug Safety Atrial Fibrillation: The Emerging Role of Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease
Current Pharmaceutical Design Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets Relationship between Diabetes Mellitus and Coronary Heart Disease
Current Diabetes Reviews Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Tenofovir-Related Nephropathies in HIV-Infected Patients
Current Vascular Pharmacology Green Synthesis of Zinc Oxide Nanoparticles (ZnO NPs) using Aqueous Extract of <i>Tagetes Erecta</i> flower and Evaluation of its Antioxidant, Antimicrobial, and Cytotoxic activities on HeLa cell line.
Current Biotechnology Patent Annotations
Recent Patents on Anti-Infective Drug Discovery The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review
Current Cardiology Reviews Drug Interactions During Periodontal Therapy in HIV-Infected Subjects
Mini-Reviews in Medicinal Chemistry Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Immune Response Towards Snake Venoms
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Thematic Issue: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part I))
Current Molecular Pharmacology Synthesis, Characterizations and Microbial Studies of Novel Mannich Products Using Multicomponent Reactions
Current Bioactive Compounds